Abstract:
Our understanding of COVID-19 vaccinations and their impact on health and mortality has evolved
substantially since the first vaccine rollouts. Published reports from the original randomized phase 3 trials
concluded that the COVID-19 mRNA vaccines could greatly reduce COVID-19 symptoms. In the interim,
problems with the methods, execution, and reporting of these pivotal trials have emerged. Re-analysis of
the Pfizer trial data identified statistically significant increases in serious adverse events (SAEs) in the
vaccine group. Numerous SAEs were identified following the Emergency Use Authorization (EUA), including
death, cancer, cardiac events, and various autoimmune, hematological, reproductive, and neurological
disorders. Furthermore, these products never underwent adequate safety and toxicological testing in
accordance with previously established scientific standards. Among the other major topics addressed in this
narrative review are the published analyses of serious harms to humans, quality control issues and process-
related impurities, mechanisms underlying adverse events (AEs), the immunologic basis for vaccine
inefficacy, and concerning mortality trends based on the registrational trial data. The risk-benefit imbalance
substantiated by the evidence to date contraindicates further booster injections and suggests that, at a
minimum, the mRNA injections should be removed from the childhood immunization program until proper
safety and toxicological studies are conducted. Federal agency approval of the COVID-19 mRNA vaccines on
a blanket-coverage population-wide basis had no support from an honest assessment of all relevant
registrational data and commensurate consideration of risks versus benefits. Given the extensive, well-
documented SAEs and unacceptably high harm-to-reward ratio, we urge governments to endorse a global
moratorium on the modified mRNA products until all relevant questions pertaining to causality, residual
DNA, and aberrant protein production are answered.